Celea Therapeutics is focused on advancing deupirfenidone (LYT-100), a deuterated form of pirfenidone, as a potential new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung conditions. Deupirfenidone has Orphan Drug Designation from the U.S. FDA and the European Commission and completed a Phase 2b (ELEVATE IPF) trial that demonstrated potential stabilization of lung function over at least 26 weeks, with open-label extension data suggesting effects through 52 weeks. The company plans to initiate the pivotal global Phase 3 SURPASS-IPF head-to-head trial versus pirfenidone in early Q3 2026. Celea was founded by PureTech Health and is based in Boston. The company announced a $180 million financing to fund the planned Phase 3 program and further development activities.

Total raised

$180M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2026